Results of a real-world study suggest that early death may be common among cancer patients taking immune checkpoint inhibitors.
Cancer patients with type 2 diabetes may have worse survival outcomes on immune checkpoint inhibitor therapy, a new study suggests.
Patient-centered methodology-generated probabilities better identify patients eligible for sentinel lymph node biopsy than those generated by conventional logistic regression analysis.
Significantly higher response rate and longer progression-free survival seen for patients with normal vitamin D.
In a phase 2 trial, pembrolizumab produced an overall response rate of 89% in patients with unresectable desmoplastic melanoma.